Relationship between glycemic control and histochemical myeloperoxidase activity in neutrophils in patients with type 2 diabetes

Diabetology & Metabolic Syndrome

Zahit Bolaman⁴  Gurhan Kadikoylu⁴  Mevlut Ture³  Imran Kurt Omurlu³  Engin Guney²  Firuzan Kacar¹  Irfan Yavasoglu⁴  Mustafa Unubol² 

[1] Department of Pathology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey;Department of Endocrinology, Faculty of Medicine, Adnan Menderes University, Aydın, 09100, Turkey;Department of Biostatistics, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey;Department of Hematology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey

关键词: Diabetic complications;    Glycemic control;    Myeloperoxidase activity;    Diabetes mellitus;   

Others  :  1235144
DOI  :  10.1186/s13098-015-0115-3

 received in 2015-09-01, accepted in 2015-12-19,  发布年份 2015

【 摘 要 】

Background

Myeloperoxidase (MPO) is a lysosomal hemoprotein found in the azurophilic granules in neutrophils. Myeloperoxidase plays an important role in oxygen-dependent killing of bacteria, fungi, virus and malignant cells. Diabetes mellitus (DM) is listed among conditions that may lead to secondary MPO deficiency in neutrophils but inconsistent results concerning MPO activity in diabetic patients have been reported in the literature. In this study, we aimed to evaluate the relationship between glycemic control in patients with type 2 DM and MPO activity in neutrophils from a histochemical perspective.

Methods

The study included 40 patients with type 2 DM with poor glycemic control, 30 patients with type 2 DM with good glycemic control and 31 healthy controls. Peripheral blood smears were analyzed for each patient included in the study. Myeloperoxidase dye was used for staining. Myeloperoxidase ratios in neutrophil were evaluated for proportions of staining with MPO in 100 neutrophils in each smear. SPSS 16.0 version was used for statistical analyses.

Results

Myeloperoxidase ratios in neutrophils were 70 (58.5–80) in type 2 DM patients with poor glycemic control compared to 80 (73.75–90) in those with good glycemic control and 88 (78–92) in healthy controls. The DM group with poor glycemic control was statistically significantly different from the other groups (p < 0.001).

Conclusions

Poor glycemic control in diabetic patients results in decreased MPO activity in neutrophils histochemically.

【 授权许可】

   
2015 Unubol et al.

【 图 表 】

Fig.1.

Fig.2.

Fig.3.

【 参考文献 】

• [1]Hatanaka E, Monteagudo PT, Marrocos MS, Campa A: Neutrophils and monocytes as potentially important sources of proinflammatory cytokines in diabetes. Clin Exp Immunol 2006, 146:443-447.
• [2]Herrera BS, Hasturk H, Kantarci A, Freire MO, Nguyen O, Kansal S, et al.: Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes. Infect Immun 2015, 83:792-801.
• [3]de Vries MA, Alipour A, Klop B, van de Geijn GJ, Janssen HW, Njo TL, et al.: Glucose-dependent leukocyte activation in patients with type 2 diabetes mellitus, familial combined hyperlipidemia and healthy controls. Metabolism. 2015, 64:213-217.
• [4]Krol E, Agueel R, Banue S, Smogorzewski M, Kumar D, Massry SG: Amlodipine reverses the elevation in [Ca2 +]i and the impairment of phagocytosis in PMNLs of NIDDM patients. Kidney Int 2003, 64:2188-2195.
• [5]Sefil F, Ulutas KT, Dokuyucu R, Sumbul AT, Yengil E, Yagiz AE, et al.: Investigation of neutrophil lymphocyte ratio and blood glucose regulation in patients with type 2 diabetes mellitus. J Int Med Res 2014, 42:581-588.
• [6]Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
• [7]Nauseef WM: Diagnostic assays for myeloperoxidase and myeloperoxidase deficiency. Methods Mol Biol 2014, 1124:537-546.
• [8]Lanza F: Clinical manifestation of myeloperoxidase deficiency-Review. J Mol Med (Berl). 1998, 76:676-681.
• [9]Marchetti C, Patriarca P, Solero GP, Baralle FE, Romano M: Genetic characterization of myeloperoxidase deficiency in Italy. Hum Mutat 2004, 23:496-505.
• [10]Dinauer MC, Newburger PE: The phagocyte system and disorders of granulopoiesis and granulocyte function. In Nathan and Oski’s Hematology of Infancy and Childhood. Edited by Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE. Saunders-Elsevier, Philadelphia; 2009:1109-1221.
• [11]Abdi Liaie Z, Soudbakhsh A, Atarod L, Toogeh GH, Nakhjavani M, Mousavipanah P, et al.: Myeloperoxidase deficiency in neutrophils of diabetic patients with and without infectious disease. Tehran Univ Med J 2008, 65(12):31-35.
• [12]Sato N, Shimizu H, Suwa K, Shimomura Y, Kobayashi I, Mori M: MPO activity and generation of active O 2 species in leukocytes from poorly controlled diabetic patients. Diabetes Care 1992, 15:1050-1052.
• [13]Gorudko IV, Kostevich AV, Sokolov AV, Konstatinova EÉ, Tsapaeva NL, Mironova EV, et al.: Increased myelopepoxidase activity is a risk factor for ishemic heart disease in patients with diabetes mellitus. Biomed Khim. 2012, 58:475-484.
• [14]American Diabetes Association: Executive summary: standards of medical care in diabetes-2014 Diabetes Care 2014, 37(Suppl 1):S5-S13.
• [15]Kitahara M, Simonian Y, Eyre HJ: Neutrophil myeloperoxidase: a simple, reproducible technique to determine activity. J Lab Clin Med 1979, 93:232-237.
• [16]Nita C, Bala C, Porojan M, Hancu N: Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study. Diabetol Metab Syndr. 2014, 6:30. BioMed Central Full Text
• [17]Uchimura K, Nagasaka A, Hayashi R, Makino M, Nagata M, Kakizawa H, et al.: Changes in superoxide dismutase activities and concentrations and myeloperoxidase activities in leukocytes from patients with diabetes mellitus. J Diabetes Complications 1999, 13:264-270.
• [18]Moldoveanu E, Tanaseanu C, Tanaseanu S, Kosaka T, Manea G, Marta DS, et al.: Plasma markers of endothelial dysfunction in type 2 diabetics. Eur J Intern Med. 2006, 17:38-42.
• [19]Gómez-García A, Rodríguez MR, Gómez-Alonso C, Ochoa DYR, Alvarez-Aguilar C: Myeloperoxidase is associated with insulin resistance and inflammation in overweight subjects with first-degree relatives with type 2 diabetes mellitus. Diabetes Metab J. 2015, 39:59-65.
• [20]de Souza Ferreira C, Araújo TH, Ângelo ML, Pennacchi PC, Okada SS, de Araújo Paula FB, et al.: Neutrophil dysfunction induced by hyperglycemia: modulation of myeloperoxidase activity. Cell Biochem Funct 2012, 30:604-610.
• [21]Saito Y, Takahashi I, Iwane K, Okubo N, Nishimura M, Matsuzaka M, et al.: The influence of blood glucose on neutrophil function in individuals without diabetes. Luminescence 2013, 28:569-573.
• [22]Alba-Loureiro TC, Munhoz CD, Martins JO, Cerchiaro GA, Scavone C, Curi R, et al.: Neutrophil function and metabolism in individuals with diabetes mellitus (Review). Braz J Med Biol Res 2007, 40:1037-1044.
• [23]Gallacher SJ, Thomson G, Fraser WD, Fisher BM, Gemmell CG, MacCuish AC: Neutrophil bactericidal function in diabetes mellitus: evidence for association with blood glucose control. Diabet Med 1995, 12:916-920.
• [24]Ayilavarapu S, Kantarci A, Fredman G, Turkoglu O, Omori K, Liu H, Iwata T, Yagi M, Hasturk H, Van Dyke TE: Diabetes-induced oxidative stress is mediated by Ca 2+ independent phospholipase A2 in neutrophils. J Immunol 2010, 184:1507-1515.
• [25]Tong PC, Lee KF, So WY, et al.: White blood cell count is associated with macro and microvascular complications in Chinese patients with type 2 diabetes. Diabetes Care 2004, 27:216-222.
• [26]Lou M, Luo P, Tang R, Peng Y, Yu S, Huang W, He L: Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients. BMC Endocr Disord. 2015, 2(15):9. BioMed Central Full Text
• [27]Muchova J, Liptakova A, Orszaghova Z, Garaiova I, Tison P, Carsky J, Durackova Z: Antioxidant systems in polymorphonuclear leucocytes of type 2 diabetes mellitus. Diabet Med 1999, 16:74-78.
• [28]Goh SY, Cooper ME: Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008, 93:1143-1152.
• [29]Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
• [30]Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, et al.: N–ε–(carboxymethyl) lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996, 35:8075-8083.
• [31]Klebanoff SJ: Myeloperoxidase: friend and foe (Review). J Leukoc Biol 2005, 77:598-625.
• [32]Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A: Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol 2000, 1041:10-15.
• [33]Tang WH, Wu Y, Nicholls SJ, Hazen SL: Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem 2011, 57:33-39.
• [34]Golubinskaya V, Brandt-Eliasson U, Gan LM, Kjerrulf M, Nilsson H: Endothelial function in a mouse model of myeloperoxidase deficiency. Biomed Res Int. 2014, 2014:128046.
• [35]Jay D, Hitomi H, Griendling KK: Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 2006, 40:183-192.
• [36]Nasr CE, Hoogwerf BJ, Faiman C, Reddy SS: United Kingdom Prospective Diabetes Study (UKPDS). Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus. Cleve Clin J Med. 1999, 66:247-253.
• [37]Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, et al.: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136-2142.